Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?
- 978 Downloads
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug, belimumab, is a monoclonal antibody that neutralizes the B-cell survival factor, B-lymphocyte stimulator (BLyS). Although belimumab has demonstrated a very favorable safety profile, many SLE patients have failed to clinically improve from belimumab therapy. Three additional BLyS antagonists (atacicept, blisibimod, tabalumab) are currently undergoing clinical testing. These antagonists subtly differ from belimumab in their biologic targets, and each is administered through a route (subcutaneous) that differs from the route through which belimumab is currently delivered (intravenous). Whether these differences will have meaningful consequences for efficacy and safety remains to be determined.
KeywordsAPRIL Atacicept BCMA Belimumab Blisbimod (A-623) BLyS/BAFF BR3 Systemic lupus erythematosus Tabalumab (LY2127399) TACI SLE
Papers of particular interest, published recently, have been highlighted as: • of Importance •• of Major Importance
- 30.• Jacob CO, Guo S, Jacob N, et al. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum 2012; 64:1610–9. This is the first and only study to date in human or murine SLE to examine the effects of APRIL neutralization/elimination (without concurrent neutralization/elimination of BLyS) on development of SLE features. Google Scholar
- 37.• Watanabe R, Ishiura N, Nakashima H, et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 2010;184:4801–4809. This study demonstrated that the B10 subset of B cells has regulatory activity and plays a role in modulating disease activity in murine SLE. PubMedCrossRefGoogle Scholar
- 38.• Iwata Y, Matsushita T, Horikawa M, et al.: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117:530–541. This study documented the human equivalent of murine B10 regulatory cells. By implication, indiscriminate depletion of B cells would eliminate these regulatory cells and could be counterproductive in the treatment of human SLE. PubMedCrossRefGoogle Scholar
- 40.• Zhou X, Xia Z, Lan Q, et al.: BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS ONE 2011;6:e23629. This study documented the ability of BLyS to directly act upon T cells and to promote generation of proinflammatory Th17 cells. The ramification for SLE is that therapeutic neutralization of BLyS may not only be beneficial by inhibiting pathogenic autoreactive B cells, but may also be beneficial by inhibiting generation of pathogenic Th17 cells. PubMedCrossRefGoogle Scholar
- 43.• Wallace DJ, Stohl W, Furie RA, et al.: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168–1178. The post-hoc analysis of this phase 2 study of belimumab in SLE set the stage for the seminal phase 3 studies that ultimately led to approval of belimumab by the FDA. PubMedCrossRefGoogle Scholar
- 44.•• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31. The BLISS-52 [44••] and BLISS-76 [45••] trials are the successful phase 3 studies in SLE that led to approval of belimumab by the FDA. PubMedCrossRefGoogle Scholar
- 45.•• Furie R, Petri M, Zamani O, et al.: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–3930. The BLISS-52 [44••] and BLISS-76 [45••] trials are the successful phase 3 studies in SLE that led to approval of belimumab by the FDA. PubMedCrossRefGoogle Scholar
- 47.•• Furie RA, Petri MA, Wallace DJ, et al.: Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143–1151. This paper describes the development of the novel SLE Responder Index (SRI), the instrument that was utilized in the BLISS-52 and BLISS-76 trials and that is now being utilized in several other SLE clinical trials. PubMedCrossRefGoogle Scholar
- 50.Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142–50.PubMedCrossRefGoogle Scholar